--- title: "Evotec (XTRA:EVT) Stock Faces Deeper EBITDA Losses After Guidance Cut" type: "News" locale: "en" url: "https://longbridge.com/en/news/295877811.md" description: "Evotec reported a H1 adjusted EBITDA loss of €42.7m and cut full-year guidance to a deeper loss of €70m-€105m. Revenue fell 19% to €156.6m, with net losses widening significantly compared to the prior year. The company attributes margin pressure to heavy fixed costs and deferred revenue shifting to 2027, highlighting challenges in converting its partnership pipeline into immediate earnings despite rising inquiry levels." datetime: "2026-08-14T03:34:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295877811.md) - [en](https://longbridge.com/en/news/295877811.md) - [zh-HK](https://longbridge.com/zh-HK/news/295877811.md) generator: "portal-rs" --- # Evotec (XTRA:EVT) Stock Faces Deeper EBITDA Losses After Guidance Cut Evotec heads into this earnings day with the stock trading at €3.548, roughly flat over the past week but still sharply weaker over three months. That sets the emotional backdrop, with investors already tired from a long slide before even opening the latest report. The headline this quarter is not revenue size; it is profitability pressure. H1 adjusted group EBITDA came in at a loss of €42.7m and management cut full year guidance to a deeper adjusted EBITDA loss of €70m to €105m. The market now has to decide whether this is a temporary funding of future deals or a more stubborn margin squeeze. Like the Evotec story but uncomfortable with the current EBITDA losses and guidance cut? Check out 295 resilient stocks with low risk scores as a benchmark for stocks with sturdier balance sheets and more resilient earnings profiles. ## Q2 2026 Earnings Summary - **Revenue, Q1 2026 vs. Q1 2025:** €156.644m vs. €199.978m (revenue declined) - **Net Loss, Q1 2026 vs. Q1 2025:** €121.936m loss vs. €31.577m loss (loss widened) - **Basic EPS, Q1 2026 vs. Q1 2025:** €0.686721 loss per share vs. €0.177872 loss per share (loss per share widened) - **H1 2026 Adjusted Group EBITDA vs. H1 2025:** €42.7m loss vs. prior year profit (profitability moved into loss territory) Prefer clear visuals over another page of earnings figures and guidance cuts? See Evotec's full financial picture, including how its balance sheet looks after this period of rising losses in the company report for Evotec. XTRA:EVT Trailing 12-Month Earnings & Revenue History as at Aug 2026 ## Evaluating Evotec’s Asset Light Bull Story Against H1 The bullish pitch around Evotec is that an asset light, data and AI driven model plus Just Evotec Biologics can support higher margin, recurring revenue over time. H1 results only partially back that up. Management reports a healthy pipeline of 10 to 20 partnership opportunities and stronger commercial activity in discovery and development services, with inbound inquiries and proposals both rising and base business net sales up around 28% year on year. That is real progress on deal flow, which is a key milestone for this thesis. However, the key financial test is conversion of this activity into revenue and royalties. Here the evidence is weaker. H1 revenue fell 19% and adjusted EBITDA moved into loss. The guidance cut and the shift of an estimated 65% of deferred revenue into 2027 indicate that the business model is not yet delivering the smoother, higher quality earnings profile that the bullish story assumes. Compare Evotec’s growing pipeline and rising inquiry levels with what institutional analysts are signalling. See the consensus price target analysis for Evotec to check how far the street’s targets sit from where the stock is trading today. ## Bear Case On Evotec’s Earnings Power Finds Support The bearish view on Evotec is that weak biotech funding, lumpy milestones and a heavy cost base could keep revenue soft while margins stay under strain. H1 2026 largely lines up with that concern. Group revenue fell 19% and adjusted EBITDA swung to a €42.7m loss, which means the fixed cost base is still too heavy for the current demand level. The guidance reset to a full year adjusted EBITDA loss of €70m to €105m confirms that margin repair is not a near term story. Bears also worry that execution risk in partnership deals can push out earnings. Management now expects around 65% of deferred partnership revenue to move into 2027 and has already baked in limited contribution from new deals in H2 2026. That is a clear milestone miss on the timing of the asset light transition, even if the underlying pipeline remains described as intact. After such a sharp move into adjusted EBITDA losses and a heavier guidance cut, it is fair to ask whether Evotec’s margin pressure, shifting revenue timing and volatile share price are isolated issues or signals of deeper structural strain. Review the independent risk analysis for Evotec which shows 1 important warning sign ## Stay Ahead With Simply Wall St If Evotec’s wider losses and deferred revenue timing have you interested but cautious, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how new information shifts the risk and reward. When you decide to take a position, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter for your holdings. For a broader view, tap into crowd wisdom through the Community and see how other investors are thinking about companies facing similar earnings pressure. By surfacing potential catalysts and risks early, Simply Wall St helps you act with more confidence and stay a step ahead of the market. ## Seeking Alternatives Beyond Evotec Today Fresh stock ideas can move from quiet to flying quickly. Use these focused shortlists while information is still under the radar for now and before momentum gets fully caught. - Spot companies quietly building momentum before headlines catch up by scanning the curated 584 high quality undiscovered gems that still trade like yesterday’s story while their fundamentals keep improving. - Track potential breakouts in the backbone of future infrastructure by following the hand picked 35 power grid technology and infrastructure stocks that could benefit if grid upgrades keep gathering speed. - Consider opportunities ahead of capital rotating toward stronger balance sheets by reviewing the filtered list of solid balance sheet and fundamentals stocks (429 results) that aim to hold up better when markets get choppy. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Evotec might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [EVO.US](https://longbridge.com/en/quote/EVO.US.md) - [EVT.DE](https://longbridge.com/en/quote/EVT.DE.md) ## Related News & Research - [EVT: Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026](https://longbridge.com/en/news/295748980.md) - [Evotec cuts FY2026 revenue outlook to EUR 570-610 million](https://longbridge.com/en/news/292523984.md) - [WeMasterTrade Receives Best Instant Prop APAC 2026 Recognition from TrustFinance Awards](https://longbridge.com/en/news/296793684.md) - [OpenPayd integrates with Circle Payments Network to enable near-instant global fiat payments to businesses](https://longbridge.com/en/news/296875082.md) - [Avricore Health’s HealthTab signs multi-year collaboration with Abbott for UK point-of-care testing distribution](https://longbridge.com/en/news/296474749.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**